[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Bristol-Myers Squibb (BMY)

Bristol-Myers Squibb (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 136,473,776
  • Shares Outstanding, K 2,042,715
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 14,442 M
  • EBITDA $ 18,453 M
  • 60-Month Beta 0.22
  • Price/Sales 2.82
  • Price/Cash Flow 8.19
  • Price/Book 6.09

Options Overview Details

View History
  • Implied Volatility 25.16% (-1.01%)
  • Historical Volatility 23.01%
  • IV Percentile 11%
  • IV Rank 22.77%
  • IV High 40.88% on 11/19/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 2) 1.16 (1.73%)
  • Put/Call Vol Ratio 0.55
  • Today's Volume 8,819
  • Volume Avg (30-Day) 25,096
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 701,375
  • Open Int (30-Day) 721,751
  • Expected Range 65.76 to 68.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $1.68
  • Number of Estimates 9
  • High Estimate $1.75
  • Low Estimate $1.59
  • Prior Year $1.63
  • Growth Rate Est. (year over year) +3.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
63.00 +6.22%
on 08/12/26
68.64 -2.51%
on 08/19/26
+1.61 (+2.47%)
since 07/31/26
3-Month
53.44 +25.22%
on 06/18/26
68.64 -2.51%
on 08/19/26
+11.97 (+21.78%)
since 06/01/26
52-Week
42.52 +57.38%
on 10/29/25
68.64 -2.51%
on 08/19/26
+19.74 (+41.84%)
since 08/29/25

Most Recent Stories

More News
Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest

Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest

BMY : 66.92 (+0.16%)
3 Reasons to Sell BMY and 1 Stock to Buy Instead

3 Reasons to Sell BMY and 1 Stock to Buy Instead

BMY : 66.92 (+0.16%)
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

New single-arm, open-label data extend the body of evidence supporting consistent clinical benefit and safety with Camzyos , adding to the longest-running clinical development experience...

BMY : 66.92 (+0.16%)
1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges

1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges

BAC : 61.99 (+0.08%)
FLEX : 106.86 (-2.19%)
BMY : 66.92 (+0.16%)
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END

SBFM : 1.1300 (+0.89%)
AZN : 162.47 (+0.21%)
MRNA : 154.27 (+9.93%)
BNTX : 101.94 (+0.33%)
BMY : 66.92 (+0.16%)
A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

NEW YORK, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - If watching where cancer treatment is headed, mRNA cancer vaccines are hard to ignore—especially in lung cancer. The...

SBFM : 1.1300 (+0.89%)
AZN : 162.47 (+0.21%)
MRNA : 154.27 (+9.93%)
BMY : 66.92 (+0.16%)
BNTX : 101.94 (+0.33%)
BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

MRK : 149.86 (+1.42%)
IBB : 210.82 (+0.85%)
MRNA : 154.27 (+9.93%)
XBI : 163.40 (+0.55%)
PFE : 28.55 (+0.32%)
BNTX : 101.94 (+0.33%)
BMY : 66.92 (+0.16%)
Turn Bristol-Myers Squibb into an Income Machine with This Options Play

With markets coming in to a volatile time of year, investors might be more interested in generating income rather than capital gains.

BMY : 66.92 (+0.16%)
1 Momentum Stock on Our Buy List and 2 We Turn Down

1 Momentum Stock on Our Buy List and 2 We Turn Down

BRC : 90.39 (-0.29%)
CATY : 60.73 (-0.78%)
BMY : 66.92 (+0.16%)
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

Approval based on EXCALIBER-RRMM results showing ZDd doubled minimal residual disease-negative complete response rates versus daratumumab, bortezomib and dexamethasone (41% vs. 21%) in relapsed or refractory...

BMY : 66.92 (+0.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 69.15
2nd Resistance Point 68.60
1st Resistance Point 67.76
Last Price 66.92
1st Support Level 66.36
2nd Support Level 65.81
3rd Support Level 64.97

See More

52-Week High 68.64
Last Price 66.92
Fibonacci 61.8% 58.66
Fibonacci 50% 55.58
Fibonacci 38.2% 52.50
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.